^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
ProstVac (rilimogene galvacirepvec)
i
Other names: recombinant vaccinia virus vaccine, vaccinia PSA Tricom-fowlpox PSA Tricom, recombinant vaccinia-fowlpox-prostate-specific antigen-TRICOM vaccine
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Bavarian Nordic, National Cancer Institute
Drug class:
Immunostimulant, KLKB1 inhibitor
Related drugs:
5ms
Programmed death-1 inhibition increases vaccine-induced T-cell infiltration in patients with prostate cancer. (PubMed, J Immunother Cancer)
Neoadjuvant PROSTVAC in combination with nivolumab is associated with increased intratumoral T-cell infiltrates, increased circulating tumor-associated antigen-specific T cells, and with radiographic and biochemical responses in the mCRPC setting. Our findings support the idea that the addition of a vaccine to a tumor-associated antigen might improve the clinical activity of immune checkpoint inhibition.
Journal • Tumor mutational burden • MSi-H Biomarker • PD(L)-1 Biomarker • IO biomarker
|
PD-L1 (Programmed death ligand 1) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability) • CD8 (cluster of differentiation 8) • MUC1 (Mucin 1) • CD4 (CD4 Molecule)
|
PD-L1 expression • TMB-H • MSI-H/dMMR
|
Opdivo (nivolumab) • ProstVac (rilimogene galvacirepvec)
over1year
16-C-0048: Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer (clinicaltrials.gov)
P2, N=74, Completed, National Cancer Institute (NCI) | Trial completion date: Aug 2024 --> Dec 2023 | Active, not recruiting --> Completed
Trial completion • Trial completion date • Metastases
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
docetaxel • ProstVac (rilimogene galvacirepvec)
over1year
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer (clinicaltrials.gov)
P1/2, N=24, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Trial completion • Combination therapy
|
CD4 (CD4 Molecule)
|
Opdivo (nivolumab) • ProstVac (rilimogene galvacirepvec)
over1year
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy (clinicaltrials.gov)
P2, N=33, Completed, Medical University of South Carolina | Active, not recruiting --> Completed
Trial completion
|
ProstVac (rilimogene galvacirepvec)
almost2years
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2024 --> Jan 2025 | Trial primary completion date: Jan 2024 --> Jan 2025
Trial completion date • Trial primary completion date
|
bintrafusp alfa (M7824) • Panvac-VF (falimarev/inalimarev) • ProstVac (rilimogene galvacirepvec)
almost2years
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy (clinicaltrials.gov)
P2, N=33, Active, not recruiting, Medical University of South Carolina | Trial completion date: Mar 2024 --> Jun 2024 | Trial primary completion date: Dec 2023 --> Mar 2024
Trial completion date • Trial primary completion date
|
ProstVac (rilimogene galvacirepvec)
2years
16-C-0048: Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer (clinicaltrials.gov)
P2, N=74, Active, not recruiting, National Cancer Institute (NCI) | Completed --> Active, not recruiting | Trial completion date: Jul 2022 --> Aug 2024
Enrollment closed • Trial completion date • Metastases
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MUC1 (Mucin 1) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
docetaxel • ProstVac (rilimogene galvacirepvec)
2years
Adjuvant PROSTVAC-V/F in Subjects at High Risk for Relapse After Radical Prostatectomy (clinicaltrials.gov)
P2, N=33, Active, not recruiting, Medical University of South Carolina | Trial completion date: Sep 2023 --> Mar 2024 | Trial primary completion date: Sep 2023 --> Dec 2023
Trial completion date • Trial primary completion date
|
ProstVac (rilimogene galvacirepvec)
2years
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer (clinicaltrials.gov)
P1/2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Trial primary completion date: Nov 2023 --> Jun 2023
Trial primary completion date • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Opdivo (nivolumab) • ProstVac (rilimogene galvacirepvec)
2years
PROSTVAC in Combination With Nivolumab in Men With Prostate Cancer (clinicaltrials.gov)
P1/2, N=20, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting | N=29 --> 20
Enrollment closed • Enrollment change • Combination therapy • IO biomarker
|
PD-L1 (Programmed death ligand 1) • CD4 (CD4 Molecule)
|
PD-L1 expression
|
Opdivo (nivolumab) • ProstVac (rilimogene galvacirepvec)
over2years
16-C-0048: Docetaxel and PROSTVAC for Metastatic Castration-Sensitive Prostate Cancer (clinicaltrials.gov)
P2, N=74, Completed, National Cancer Institute (NCI) | Active, not recruiting --> Completed
Trial completion
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • MUC1 (Mucin 1) • TNFA (Tumor Necrosis Factor-Alpha) • CEACAM5 (CEA Cell Adhesion Molecule 5) • CD4 (CD4 Molecule) • IL2 (Interleukin 2) • LAMP1 (Lysosomal Associated Membrane Protein 1)
|
docetaxel • ProstVac (rilimogene galvacirepvec)
over2years
Combination Immunotherapy in Biochemically Recurrent Prostate Cancer (clinicaltrials.gov)
P2, N=29, Active, not recruiting, National Cancer Institute (NCI) | Recruiting --> Active, not recruiting
Enrollment closed
|
bintrafusp alfa (M7824) • Panvac-VF (falimarev/inalimarev) • ProstVac (rilimogene galvacirepvec)
Share via
